StockNews.com Initiates Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

Posted by Casey Walker on Feb 5th, 2025

StockNews.com initiated coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP – Free Report) in a research note published on Sunday morning. The firm issued a hold rating on the stock.

Tonix Pharmaceuticals Trading Down 22.0 %

Shares of TNXP opened at $0.15 on Friday. Tonix Pharmaceuticals has a 1-year low of $0.12 and a 1-year high of $12.48. The firm has a market capitalization of $28.43 million, a price-to-earnings ratio of 0.00 and a beta of 2.07. The firm’s 50-day moving average price is $0.30 and its 200-day moving average price is $0.27. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The firm had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. Sell-side analysts anticipate that Tonix Pharmaceuticals will post -17.63 EPS for the current year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. PFG Investments LLC purchased a new position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned about 0.12% of Tonix Pharmaceuticals as of its most recent SEC filing. 82.26% of the stock is owned by institutional investors and hedge funds.

About Tonix Pharmaceuticals

(Get Free Report)

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.